ETN, a licensed biologic, has been used for TNF-α blockade for over 20 years [64, 65] and has shown remarkable efficacy as an anti-inflammatory agent in rheumatoid arthritis and inflammatory bowel diseases [62, 66]; its safety profile is well known. Here, TNF is linked to inflammatory bowel disease.